BioCentury
ARTICLE | Company News

Sanofi sales and marketing update

October 19, 2015 7:00 AM UTC

Sanofi launched in the U.S. an authorized generic version of its Arava leflunomide to treat rheumatoid arthritis (RA). The pyrimidine synthesis inhibitor has a wholesale acquisition cost (WAC) of $5 ...